|
Market Report
|
 Female Sexual Dysfunction: Prescription Drug Pipeline Overview 2007
Female sexual dysfunction (FSD) affects an estimate 84 million women across the seven major pharmaceutical markets and represents a significant opportunity for investment. Despite its high prevalence, FSD is poorly understood and defined. Currently there is just one product approved for the treatment of FSD; P&G's Intrinsa (testosterone) is marketed in Germany, France and the UK.
|
|
Read more...
|
|
|
Company Report
|
Incremental improvements and paradigm shifts in strategy are both necessary to boost productivity
Waves of technological advancements have powered significant evolution in R&D from serendipitous drug discovery, through to rational drug design. However, as the low-hanging fruit has been picked, and recent technological advances have failed to yield high numbers of new therapies, the search is on to identify R&D strategies to improve R&D productivity.
|
|
Read more...
|
|
|
Market Report
|
Heart failure - Weak pipeline dominated by new indications and add-on diuretics
Datamonitor expects few new products to emerge from a week pipeline for both acute and chronic heart failure. Sales in the seven major markets will be modest with all the new drugs being add-on therapies to current standard regimes. Significant unmet patients needs will remain in both acute and chronic heart failure.
|
|
Read more...
|
|
|
Market Report
|
Analyzing Market Trends and Regulatory Impacts
With fewer truly novel products entering the market, combined with increasing developmental time and spend, and declining ROI, successful launches have never been more important for pharmaceutical companies. Therefore, to ensure a successful launch, manufacturers must employ a multitude of timely strategies to ensure their product enter the market as soon and as smoothly as possible.
|
|
Read more...
|
|
|
Company Report
|
Business Blogging for Pharma
Social media are shifting the way that the global economy operates. Internet journals and communities have enabled consumers to communicate their experiences with companies' products and services to other consumers. A consequence of consumer-generated marketing is that relationship management throughout the lifecycle of a product is taking the place of mass marketing in consumer-driven industries.
|
|
Read more...
|
|
|
Market Report
|
Hospital Antibacterials A market beyond MRSA
The Hospital antibacterials market accounted for $9.9bn of the total $41bn anti-infectives market. Increasingly resistant and problematic pathogens make this an attractive target for premium priced products outside of the largely genericized Community market. However, high concentrations of patent expiries and similarly targeted product launches imply a highly competitive commercial landscape.
|
|
Read more...
|
|
|
Product Report
|
Regulatory and development issues hurdles exist but are surmountable
Europe serves as a model for other countries looking to define their own regulatory approval criteria. The US is on the brink of passing legislation to establish a statutory pathway for biosimilars approval but the opposing interests of biosimilar and innovative companies may result in further delays. Development of biosimilars presents many challenges and potential pitfalls.
|
|
Read more...
|
|
|
Market Report
|
Online Pharmacies - Implications for the Pharmaceutical Industry
Online pharmacies are playing an increasing role in the prescription pharmaceutical industry as patients seek the convenience and in some cases cost benefits that they can provide. However while online pharmacies offer considerable benefits there are also risks attached to their increasing role.
|
|
Read more...
|
|
|
Product Report
|
Monoclonal Antibodies Report Part II: Companies - Holding mAbs in portfolio promises protection against the looming 2011-12 patent cliff
This report provides a comprehensive strategic analysis of the mAb market out to 2012 by company. It identifies four 'established' and four 'emerging' players within the mAb sector which are forecast to play the most commercially significant role within this market. The report assesses how these players will be insulated from the impact of generic competition as a result of mAb market penetration.
|
|
Read more...
|
|
|
Market Report
|
Migraine - Opportunities will exist in the wake of generic attack
With the seven triptan brands continuing to dominate acute migraine treatment and Ortho-McNeil's Topamax (topiramate) driving sales in the prophylactic market, 7MM revenues of anti-migraine drugs increased by 8.1% from 2005 to $3.7 billion in 2006. The US accounted for 80% of the 7MM total in 2006, Whilst in the 5EU, France is the largest market for migraine-specific drug sales.
|
|
Read more...
|
|
|
Market Report
|
Epilepsy - Companies committed to the cause will reap the benefits
The current epilepsy market boasts a wide range of treatment options and has recently reached a state of maturity. The market value across the 7MM grew by just 2.3% from 2005 to $3.2 billion in 2006. However, imminent change to the market in the near to mid term will be brought about by the occurrence of key patent expiries and new drugs launches.
|
|
Read more...
|
|
|
Market Report
|
NICE: its impact on the UK healthcare system and beyond
NICE is one of the most advanced cost effectiveness assessment bodies operating in the major pharmaceutical markets. Since it was established it has had an increasing impact on the availability of new drugs in England and Wales, but has also generated considerable attention globally.
|
|
Read more...
|
|
|
Market Report
|
Parkinson's Disease - Market to grow as first round of lifecycle management strategies succeed
The PD market is set to continue to grow over the next 7 years, reaching over $2.37 billion in 2013, a 39% increase from 2006 levels. Combinations, reformulations, and indication expansions will drive the majority of this growth, with key brands expected to be Novartis/Orion's Stalevo, GlaxoSmithKline's (GSK's) Requip Modutab, and UCB-Schwarz's Neupro.
|
|
Read more...
|
|
|
Market Report
|
Cancer Overview - Increasing diversity offers both high risk and reward
In 2007, more than 3 million new cases of solid tumors are forecast to be diagnosed across the seven major pharmaceutical markets, obviously representing an enormous market potential. Lower incidence tumor types are becoming increasingly attractive to drug developers, due to high levels of unmet need which can result in significant financial rewards.
|
|
Read more...
|
|
|
Market Report
|
Strategic issues - Potential remains uncertain
Significant barriers to entry into the biosimilars market exist. High up-front investment and the need for specific expertise favor big players. Understanding of the marketplace is critical for success acceptance by key stakeholders is crucial for market uptake of biosimilars and achieving preferential reimbursement status through constant review of the pricing strategy is desirable.
|
|
Read more...
|
|
|
Market Report
|
HIV Therapy Dynamics
Despite several developments in efforts to tackle the spread of HIV, the total number of people living with HIV has continued to increase across the 6MM. However, significant advances in HIV disease understanding, treatment and management mean that the outlook for patients has considerably improved.
|
|
Read more...
|
|
|
Market Report
|
Upper GI Disorders - Innovation needed to overcome generic threat
The upper GI market, defined as gastroesophageal reflux disease (GERD), peptic ulcer disease (PUD) and dyspepsia indications, achieved sales of just over $19 billion in 2006, with minimal growth since 2005. All major PPI brands will lose patent protection in the next 10 years, resulting in a major increase in generics and a declining market value.
|
|
Read more...
|
|
|
Market Report
|
Infertility - Optimizing a market bounded by social opinion and physician preference
The market for infertility drugs is a complex and dynamic arena shaped by numerous factors such as changing social attitudes, national legislation, and prescriber preferences. Brand strength and diverse portfolios have allowed Organon, Merck Serono and Ferring to secure a firm foothold in the market, worth over $1 billion in 2006, and represent tough competition.
|
|
Read more...
|
|
Farmavita.Net Journal 
